Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
04. August 2016 07:30 ET
|
Minerva Neurosciences, Inc.
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
28. Juli 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...